AMOMED PHARMA GmbH is an international, emerging specialty company based in Vienna, Austria. Since our establishment in 2006, we have grown into a renowned specialist for intensive care and emergency medicine, anesthesia and neuro-psychiatric products. As of September 2020, we are a Member of the AOP Orphan Group, a pioneer in the field of special diseases requiring complex management.

Our first obligation is to ensure the success of a patient’s medical treatment. To this end, we maintain close ties with medical science, yet place a strong emphasis on practical use. This makes us a sought-after partner for doctors, specialists and decision-makers.

 

Your preferred partner

We are both an expert distribution partner for hospitals and a valuable partner for medical specialists, dedicated to providing the solutions they need. Our products comprise the medication needed in critical, life-threatening situations.

Highest quality standards, delivery reliability and a strong drive for excellence as a team are fundamentally important to us. We act swiftly and flexibly to find the right solutions – in close consultation with medical specialists and for the benefit of patients. We share the responsibility for the smooth functioning of medical measures at the decisive moment. At AMOMED we are fully aware of the importance of our actions and are deeply committed to the far-reaching aspect of our work. We put our motto into practice each day: AMOMED – Medicine when it matters most.

Products

Events

Events not available

News

ICU Management

Septic Shock and Vasopressor Initiation: Why Earlier is Better

2022 16 Mar

An overview of vasopressor management, current evidence and when to initiate vasopressor therapy for best possible patient outcome. Vasopressor management is a cornerstone in the haemodynamic management of septic shock for reversing hypotension by increasing systemic vascular resistance and improving organ perfusion. The Surviving Sepsis Campaign... Read more

ICU Management

Rationale Behind Practice: Landiolol in Critical Care

2022 16 Mar

A summary of data regarding the use of landiolol as a potential immunomodulator in septic patients and its effectiveness and safety in the management of new-onset postoperative atrial fibrillation (POAF). Cardiovascular Dysfunction and Sepsis Cardiovascular dysfunction is a common complication of sepsis. Approximately 40 to 50% of patients... Read more

ICU Management

Management of Acute Arrhythmias in Patients With Cardiac Dysfunction - Update of ESC Guidelines

2021 30 Sep

In 2020, the ultra-short acting beta-blocker landiolol was first included in the ESC guidelines with a class I recommendation. The recommendations were based on study results demonstrating the rapid response, efficacy, and safety of this drug. At a recent symposium, during 2021 Heart Failure World Congress, cardiologists were invited to present... Read more

ICU Management

Vasopressor Management in Septic Shock: General Overview and Personalised Approaches

2021 24 Jun

This article summarises the proceedings of an ESICM webinar in which two experts discuss vasopressor therapy and its fundamental role in the treatment of septic shock-induced hypotension. They provide an overview of severe septic shock, the benefits of second-line vasopressors and their use in COVID-19 patients. Vasopressors in Severe Septic... Read more

ICU Management

Evidence-Based Management of Atrial Fibrillation

2021 22 Feb

The 2020 ESC Guidelines and the addition of Landiolol An overview of the updated guidelines for the diagnosis and management of atrial fibrillation, developed in association with the European Association for Cardio-Thoracic Surgery. T he European Society of Cardiology (ESC) provides a range of scientific and educational activities,... Read more

ICU Management

New ESC Guidelines for Atrial Fibrillation Published

2020 30 Nov

The European Society of Cardiology ( ESC ) has published their new guidelines for the diagnosis and treatment of atrial fibrillation during its congress this year*. The recently released guidelines replace the recommendations of the Society, which were published in 2016. One of the most interesting innovations is the approach towards characterization... Read more

ICU Management

Treatment of Catecholamine Refractory Hypotension in Septic Shock: Beyond First Line Vasopressor

2020 24 Nov

Hypotension during septic shock is a strong indicator of patient outcome and mortality. Arginine vasopressin is a naturally produced human hormone with vasoconstriction effect via V1 receptor activation and a short 5-20 minutes half-life and is recommended by the Surviving Sepsis Campaign guidelines to be added as a second-line vasoactive agent when... Read more

ICU Management

Atrial Fibrillation and Sepsis: A Life-Threatening Combination

2020 08 Oct

Almost half of the patients with sepsis suffer from myocardial depression and a reduced ejection fraction. Sepsis can also cause changes in circulating volume, vascular tone, and coronary blood flow, all of which affect heart function and heart rate. Serum catecholamine levels and direct measurements of renal sympathetic nerve activity have shown that... Read more

ICU Management

COVID-19 and the Potential Effects on the Cardiovascular System

2020 11 Aug

COVID-19 affects the myocardium and myocarditis and cardiac injury is a common condition among hospitalised patients. Landiolol, a new ultra-short acting, intravenous most  β 1 selective blocker, can help reduce inflammation and provide therapeutic benefits. Influenza, bacterial pneumonias, respiratory infections and viruses... Read more

ICU Management

Vasoactive Agent Management for Haemodynamic Support in COVID-19 Patients

2020 19 May

An overview of the Surviving Sepsis Guidelines for the vasoactive agent management of COVID-19 patients with septic shock and the use of arginine vasopressin in this patient population. The SARS-CoV-2 has caused a global health crisis. Thousands of people across the globe have been affected by COVID-19. Clinicians are in urgent need of... Read more

ICU Management

AMOMED Pharma Offers Drugs for Severe COVID-19 Cases

2020 23 Apr

AMOMED Pharma develops medicinal products for patients suffering from septic shock at the intensive care units. Septic shock is a life-threatening complication in COVID-19 patients.   Most COVID-19 admissions to the intensive care unit are due to severe lung disorders requiring invasive mechanical ventilation; many with acute respiratory distress... Read more

ICU Management

3 Practical Tools for the Daily Work in the ICU

2020 23 Apr

We created the following three practical tools for physicians and medical personnel for their daily work in the ICU related to COVID-19 and sepsis.   Recommendations for Vasoactive Management for Hemodynamic Support in COVID-19 Patients with Septic Shock SOFA Score WHO Categorization of Clinical Syndromes Associated with COVID-19 in Adults  ... Read more

ICU Management

New-Onset of Atrial Fibrillation in the ICU: a special challenge for heart failure patients

2020 23 Apr

Atrial fibrillation (AF) is the most common heartbeat irregularity and associated with development of stroke, myocardial infarction and heart failure. Vice versa, the structural and neurohormonal changes in heart failure (HF), when the contractility of the heart muscle is reduced, make the development and progression of AF much more likely.  HF itself... Read more

ICU Management

COVID-19 Online Resources for Health Care Professionals

2020 23 Apr

Below you can find a summarised overview of online resources with developments, guidelines and recommendations for physicians and medical staff for COVID-19 patients in critical condition (e.g. patients in intensive care), as well as other general resources. ICU Therapy guideline for the treatment of patients with a SARS CoV2 infection Autoren:... Read more

Jobs not available

Catalogue

    Catalogue not available

Storchengasse, 1
Vienna
1150
+43 1 545 01 13 0

White Papers - Case Studies

Not available

Videos

    Videos not available

Articles

ICU Management

Septic Shock and Vasopressor Initiation: Why Earlier is Better

2022 16 Mar

An overview of vasopressor management, current evidence and when to initiate vasopressor therapy for best possible patient outcome. Vasopressor management is a cornerstone in the haemodynamic management of septic shock for reversing hypotension by increasing systemic vascular resistance and improving organ perfusion. The Surviving Sepsis Campaign... Read more

ICU Management

Rationale Behind Practice: Landiolol in Critical Care

2022 16 Mar

A summary of data regarding the use of landiolol as a potential immunomodulator in septic patients and its effectiveness and safety in the management of new-onset postoperative atrial fibrillation (POAF). Cardiovascular Dysfunction and Sepsis Cardiovascular dysfunction is a common complication of sepsis. Approximately 40 to 50% of patients... Read more

ICU Management

Management of Acute Arrhythmias in Patients With Cardiac Dysfunction - Update of ESC Guidelines

2021 30 Sep

In 2020, the ultra-short acting beta-blocker landiolol was first included in the ESC guidelines with a class I recommendation. The recommendations were based on study results demonstrating the rapid response, efficacy, and safety of this drug. At a recent symposium, during 2021 Heart Failure World Congress, cardiologists were invited to present... Read more

ICU Management

Vasopressor Management in Septic Shock: General Overview and Personalised Approaches

2021 24 Jun

This article summarises the proceedings of an ESICM webinar in which two experts discuss vasopressor therapy and its fundamental role in the treatment of septic shock-induced hypotension. They provide an overview of severe septic shock, the benefits of second-line vasopressors and their use in COVID-19 patients. Vasopressors in Severe Septic... Read more

ICU Management

Evidence-Based Management of Atrial Fibrillation

2021 22 Feb

The 2020 ESC Guidelines and the addition of Landiolol An overview of the updated guidelines for the diagnosis and management of atrial fibrillation, developed in association with the European Association for Cardio-Thoracic Surgery. T he European Society of Cardiology (ESC) provides a range of scientific and educational activities,... Read more

ICU Management

Treatment of Catecholamine Refractory Hypotension in Septic Shock: Beyond First Line Vasopressor

2020 24 Nov

Hypotension during septic shock is a strong indicator of patient outcome and mortality. Arginine vasopressin is a naturally produced human hormone with vasoconstriction effect via V1 receptor activation and a short 5-20 minutes half-life and is recommended by the Surviving Sepsis Campaign guidelines to be added as a second-line vasoactive agent when... Read more

ICU Management

COVID-19 and the Potential Effects on the Cardiovascular System

2020 11 Aug

COVID-19 affects the myocardium and myocarditis and cardiac injury is a common condition among hospitalised patients. Landiolol, a new ultra-short acting, intravenous most  β 1 selective blocker, can help reduce inflammation and provide therapeutic benefits. Influenza, bacterial pneumonias, respiratory infections and viruses... Read more

ICU Management

Vasoactive Agent Management for Haemodynamic Support in COVID-19 Patients

2020 19 May

An overview of the Surviving Sepsis Guidelines for the vasoactive agent management of COVID-19 patients with septic shock and the use of arginine vasopressin in this patient population. The SARS-CoV-2 has caused a global health crisis. Thousands of people across the globe have been affected by COVID-19. Clinicians are in urgent need of... Read more

Blog

Not available